Epithelial-to-mesenchymal transition in diabetic nephropathy: Fact or fiction?

Cells

Volumn 4, Issue 4, 2015, Pages 631-652

  Loeffler, Ivonne ^a   Wolf, Gunter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Diabetic nephropathy; Endothelial to mesenchymal transition (EndoMT); Epithelial to mesenchymal transition (EMT); Renal fibrosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; BETA CATENIN; CALVASCULIN; CD31 ANTIGEN; COLLAGEN TYPE 1; CONNEXIN 43; GELATINASE A; GELATINASE B; GUANOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN 47; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NOTCH RECEPTOR; PROTEIN ZO1; SCATTER FACTOR; SCLEROPROTEIN; SMAD PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VASCULAR ENDOTHELIAL CADHERIN; VIMENTIN; WNT PROTEIN;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GLOMERULUS; HUMAN; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE BASEMENT MEMBRANE; MYOFIBROBLAST; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW;

EID: 84992354665     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells4040631     Document Type: Review

References (78)

1. Hu, C.; Sun, L.; Han, Y.; Fu, X.; Xiong, X.; Xu, X.; Liu, Y.; Yang, S.; Liu, F.; Kanwar, Y.S. Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy. Curr. Med. Chem. 2015, 22, 2858–2870.
2. Loeffler, I.; Liebisch, M.; Wolf, G. Collagen viii influences epithelial phenotypic changes in experimental diabetic nephropathy. American journal of physiology. Renal Physiol. 2012, 303, F733–F745.
3. Zeisberg, M.; Neilson, E.G. Mechanisms of tubulointerstitial fibrosis. J. Amer. Soc. Nephrol. 2010, 21, 1819–1834.
4. Hills, C.E.; Squires, P.E. The role of tgf-beta and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev. 2011, 22, 131–139.
5. Li, J.; Bertram, J.F. Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis. Nephrology 2010, 15, 507–512.
6. Pedagogos, E.; Hewitson, T.; Fraser, I.; Nicholls, K.; Becker, G. Myofibroblasts and arteriolar sclerosis in human diabetic nephropathy. Amer J. Kidney Dis. 1997, 29, 912–918.
7. Liu, Y. Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J. Amer. Soc. Nephrol. 2004, 15, 1–12.
8. Strutz, F.; Okada, H.; Lo, C.W.; Danoff, T.; Carone, R.L.; Tomaszewski, J.E.; Neilson, E.G. Identification and characterization of a fibroblast marker: Fsp1. J. Cell Biol. 1995, 130, 393–405.
9. Galichon, P.; Hertig, A. Epithelial to mesenchymal transition as a biomarker in renal fibrosis: Are we ready for the bedside? Fibrogenesis Tissue Repair 2011, 4, 11.
10. Iwano, M.; Plieth, D.; Danoff, T.M.; Xue, C.; Okada, H.; Neilson, E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 2002, 110, 341–350.
11. Fragiadaki, M.; Mason, R.M. Epithelial-mesenchymal transition in renal fibrosis-evidence for and against. Int. J. Exp. Pathol. 2011, 92, 143–150.
12. Zeisberg, M.; Hanai, J.; Sugimoto, H.; Mammoto, T.; Charytan, D.; Strutz, F.; Kalluri, R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nature Med. 2003, 9, 964–968.
13. Simonson, M.S. Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int. 2007, 71, 846–854.
14. Hills, C.E.; Squires, P.E. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Amer. J. Nephrol. 2010, 31, 68–74.
15. Reidy, K.; Susztak, K. Epithelial-mesenchymal transition and podocyte loss in diabetic kidney disease. Amer J. Kidney Dis. 2009, 54, 590–593.
16. Kizu, A.; Medici, D.; Kalluri, R. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J. Pathol. 2009, 175, 1371–1373.
17. Li, J.; Qu, X.; Bertram, J.F. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J. Pathol. 2009, 175, 1380–1388.
18. Srivastava, S.P.; Koya, D.; Kanasaki, K. Micrornas in kidney fibrosis and diabetic nephropathy: Roles on emt and endmt. BioMed Res. Int. 2013, 2013, 125469.
19. Zeisberg, E.M.; Potenta, S.E.; Sugimoto, H.; Zeisberg, M.; Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Amer. Soc. Nephrol.2008, 19, 2282–2287.
20. Kriz, W.; Kaissling, B.; Le Hir, M. Epithelial-mesenchymal transition (emt) in kidney fibrosis: Fact or fantasy? J. Clin. Invest. 2011, 121, 468–474.
21. Louis, K.; Hertig, A. How tubular epithelial cells dictate the rate of renal fibrogenesis? World J. Nephrol. 2015, 4, 367–373.
22. Xu, X.F.; Dai, H.P. Type 2 epithelial mesenchymal transition in vivo: Truth or pitfalls? Chin. Med. J. 2012, 125, 3312–3317.
23. Zeisberg, M.; Duffield, J.S. Resolved: Emt produces fibroblasts in the kidney. J. Amer. Soc. Nephrol. 2010, 21, 1247–1253.
24. Mandache, E.; Gherghiceanu, M.; Serafinceanu, C.; Penescu, M.; Mircescu, G. Myofibroblast involvement in tubular basement membrane remodeling in type ii diabetic nephropathy. Rom. J. Morphol. Embryol. 2011, 52, 75–79.
25. Oldfield, M.D.; Bach, L.A.; Forbes, J.M.; Nikolic-Paterson, D.; McRobert, A.; Thallas, V.; Atkins, R.C.; Osicka, T.; Jerums, G.; Cooper, M.E. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (rage). J. Clin. Invest. 2001, 108, 1853–1863.
26. Rastaldi, M.P.; Ferrario, F.; Giardino, L.; Dell’Antonio, G.; Grillo, C.; Grillo, P.; Strutz, F.; Muller, G.A.; Colasanti, G.; D’Amico, G. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int. 2002, 62, 137–146.
27. Lu, Q.; Ji, X.J.; Zhou, Y.X.; Yao, X.Q.; Liu, Y.Q.; Zhang, F.; Yin, X.X. Quercetin inhibits the mtorc1/p70s6k signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathy. Pharmacol. Res. 2015, 99, 237–247.
28. Zeng, R.; Han, M.; Luo, Y.; Li, C.; Pei, G.; Liao, W.; Bai, S.; Ge, S.; Liu, X.; Xu, G. Role of sema4c in tgf-beta1-induced mitogen-activated protein kinase activation and epithelialmesenchymal transition in renal tubular epithelial cells. Nephrol. Dialysis Transplant. 2011, 26, 1149–1156.
29. Liu, R.; Wang, Y.; Xiao, Y.; Shi, M.; Zhang, G.; Guo, B. Snon as a key regulator of the high glucose-induced epithelial-mesenchymal transition in cells of the proximal tubule. Kidney Blood Pressure Res. 2012, 35, 517–528.
30. Humphreys, B.D.; Lin, S.L.; Kobayashi, A.; Hudson, T.E.; Nowlin, B.T.; Bonventre, J.V.; Valerius, M.T.; McMahon, A.P.; Duffield, J.S. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J. Pathol. 2010, 176, 85–97.
31. Loeffler, I.; Wolf, G. Transforming growth factor-beta and the progression of renal disease. Nephrol. Dialysis Transplant. 2014, 29 (Suppl 1), i37-i45.
32. LeBleu, V.S.; Taduri, G.; O'Connell, J.; Teng, Y.; Cooke, V.G.; Woda, C.; Sugimoto, H.; Kalluri, R. Origin and function of myofibroblasts in kidney fibrosis. Nature Med. 2013, 19, 1047–1053.
33. Mack, M.; Yanagita, M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int. 2015, 87, 297–307.
34. Lin, S.L.; Kisseleva, T.; Brenner, D.A.; Duffield, J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J. Pathol. 2008, 173, 1617–1627.
35. Li, Y.; Kang, Y.S.; Dai, C.; Kiss, L.P.; Wen, X.; Liu, Y. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J. Pathol. 2008, 172, 299–308.
36. Burns, W.C.; Kantharidis, P.; Thomas, M.C. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007, 185, 222–231.
37. Lee, J.M.; Dedhar, S.; Kalluri, R.; Thompson, E.W. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J. Cell Biol.2006, 172, 973–981.
38. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196.
39. Carew, R.M.; Wang, B.; Kantharidis, P. The role of emt in renal fibrosis. Cell. Tissue Res. 2012, 347, 103–116.
40. Yang, J.; Liu, Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J. Pathol. 2001, 159, 1465–1475.
41. Phanish, M.K.; Wahab, N.A.; Colville-Nash, P.; Hendry, B.M.; Dockrell, M.E. The differential role of smad2 and smad3 in the regulation of pro-fibrotic tgfbeta1 responses in human proximaltubule epithelial cells. Biochem. J. 2006, 393, 601–607.
42. Wang, B.; Herman-Edelstein, M.; Koh, P.; Burns, W.; Jandeleit-Dahm, K.; Watson, A.; Saleem, M.; Goodall, G.J.; Twigg, S.M.; Cooper, M.E.; et al. E-cadherin expression is regulated by mir-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010, 59, 1794–1802.
43. Wang, B.; Koh, P.; Winbanks, C.; Coughlan, M.T.; McClelland, A.; Watson, A.; Jandeleit-Dahm, K.; Burns, W.C.; Thomas, M.C.; Cooper, M.E.; et al. Mir-200a prevents renal fibrogenesis through repression of tgf-beta2 expression. Diabetes 2011, 60, 280–287.
44. Yamaguchi, Y.; Iwano, M.; Suzuki, D.; Nakatani, K.; Kimura, K.; Harada, K.; Kubo, A.; Akai, Y.; Toyoda, M.; Kanauchi, M.; et al. Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Amer J. Kidney Dis. 2009, 54, 653–664.
45. Zheng, M.; Lv, L.L.; Ni, J.; Ni, H.F.; Li, Q.; Ma, K.L.; Liu, B.C. Urinary podocyte-associated mrna profile in various stages of diabetic nephropathy. PloS ONE 2011, 6, e20431.
46. Dai, H.Y.; Zheng, M.; Tang, R.N.; Ni, J.; Ma, K.L.; Li, Q.; Liu, B.C. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy. Amer. J. Med. Sci. 2011, 341, 207–214.
47. Li, J.; Qu, X.; Yao, J.; Caruana, G.; Ricardo, S.D.; Yamamoto, Y.; Yamamoto, H.; Bertram, J.F. Blockade of endothelial-mesenchymal transition by a smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59, 2612–2624.
48. Guerrot, D.; Dussaule, J.C.; Kavvadas, P.; Boffa, J.J.; Chadjichristos, C.E.; Chatziantoniou, C. Progression of renal fibrosis: The underestimated role of endothelial alterations. Fibrogenesis Tissue Repair 2012, 5, S15.
49. He, J.; Xu, Y.; Koya, D.; Kanasaki, K. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin. Exp. Nephrol. 2013, 17, 488–497.
50. Piera-Velazquez, S.; Li, Z.; Jimenez, S.A. Role of endothelial-mesenchymal transition (endomt) in the pathogenesis of fibrotic disorders. Am J. Pathol. 2011, 179, 1074–1080.
51. Zeisberg, M.; Neilson, E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119, 1429–1437.
52. Zhang, A.; Wang, M.H.; Dong, Z.; Yang, T. Prostaglandin e2 is a potent inhibitor of epithelial-tomesenchymal transition: Interaction with hepatocyte growth factor. Amer. J. Physiol-Renal Physiol. 2006, 291, F1323–F1331.
53. Park, S.H.; Choi, M.J.; Song, I.K.; Choi, S.Y.; Nam, J.O.; Kim, C.D.; Lee, B.H.; Park, R.W.; Park, K.M.; Kim, Y.J.; et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: Role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J. Amer. Soc. Nephrol.2007, 18, 1497–1507.
54. Burns, W.C.; Twigg, S.M.; Forbes, J.M.; Pete, J.; Tikellis, C.; Thallas-Bonke, V.; Thomas, M.C.; Cooper, M.E.; Kantharidis, P. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J. Amer. Soc. Nephrol.2006, 17, 2484–2494.
55. Lee, J.H.; Kim, J.H.; Kim, J.S.; Chang, J.W.; Kim, S.B.; Park, J.S.; Lee, S.K. Amp-activated protein kinase inhibits tgf-beta-, angiotensin ii-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Amer. J. Physiol-Renal Physiol. 2013, 304, F686–F697.
56. Liu, L.; Fu, W.; Xu, J.; Shao, L.; Wang, Y. Effect of bmp7 on podocyte transdifferentiation and smad7 expression induced by hyperglycemia. Clin. Nephrol. 2015, 84, 95–99.
57. Ibrini, J.; Fadel, S.; Chana, R.S.; Brunskill, N.; Wagner, B.; Johnson, T.S.; El Nahas, A.M. Albumininduced epithelial mesenchymal transformation. Nephron Exp. Nephrol. 2012, 120, e91–e102.
58. Zheng, G.P.; Lyons, J.G.; Tan, T.K.; Wang, Y.P.; Hsu, T.T.; Min, D.Q.; Succar, L.; Rangan, G.K.; Hu, M.; Henderson, B.R.; et al. Disruption of e-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factorbeta 1 in renal tubular epithelial cells. Amer. J. Pathol.2009, 175, 580–591.
59. Kang, Y.S.; Li, Y.; Dai, C.; Kiss, L.P.; Wu, C.; Liu, Y. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int. 2010, 78, 363–373.
60. Okada, H.; Danoff, T.M.; Kalluri, R.; Neilson, E.G. Early role of fsp1 in epithelial-mesenchymal transformation. Amer. J. Physiol. 1997, 273, F563–F574.
61. Yang, J.; Liu, Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J. Amer. Soc. Nephrol. 2002, 13, 96–107.
62. Cufi, S.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Martin-Castillo, B.; Joven, J.; Menendez, J.A. Metformin against tgfbeta-induced epithelial-to-mesenchymal transition (emt): From cancer stem cells to aging-associated fibrosis. Cell. Cycle 2010, 9, 4461–4468.
63. Hills, C.E.; Siamantouras, E.; Smith, S.W.; Cockwell, P.; Liu, K.K.; Squires, P.E. TGF beta modulates cell-to-cell communication in early epithelial-to-mesenchymal transition. Diabetologia 2012, 55, 812–824.
64. Hills, C.E.; Price, G.W.; Squires, P.E. Mind the gap: Connexins and cell-cell communication in the diabetic kidney. Diabetologia 2015, 58, 233–241.
65. Hills, C.E.; Kerr, M.I.; Wall, M.J.; Squires, P.E. Visfatin reduces gap junction mediated cell-tocell communication in proximal tubule-derived epithelial cells. Cell. Physiol. Biochem. 2013, 32, 1200–1212.
66. Zheng, M.; Lv, L.L.; Cao, Y.H.; Zhang, J.D.; Wu, M.; Ma, K.L.; Phillips, A.O.; Liu, B.C. Urinary mrna markers of epithelial-mesenchymal transition correlate with progression of diabetic nephropathy. Clin. Endocrinol. 2012, 76, 657–664.
67. Doublier, S.; Salvidio, G.; Lupia, E.; Ruotsalainen, V.; Verzola, D.; Deferrari, G.; Camussi, G. Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin ii. Diabetes 2003, 52, 1023–1030.
68. Turk, T.; Leeuwis, J.W.; Gray, J.; Torti, S.V.; Lyons, K.M.; Nguyen, T.Q.; Goldschmeding, R. Bmp signaling and podocyte markers are decreased in human diabetic nephropathy in association with ctgf overexpression. J Histochem. Cytochem. 2009, 57, 623–631.
69. Cook, H.T. The origin of renal fibroblasts and progression of kidney disease. Am J. Pathol. 2010, 176, 22–24.
70. Koesters, R.; Kaissling, B.; Lehir, M.; Picard, N.; Theilig, F.; Gebhardt, R.; Glick, A.B.; Hahnel, B.; Hosser, H.; Grone, H.J.; et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J. Pathol. 2010, 177, 632–643.
71. Faulkner, J.L.; Szcykalski, L.M.; Springer, F.; Barnes, J.L. Origin of interstitial fibroblasts in an accelerated model of angiotensin ii-induced renal fibrosis. Am J. Pathol. 2005, 167, 1193–1205.
72. Ru, Y.; Eyden, B.; Curry, A.; McWilliam, L.J.; Coyne, J.D. Actin filaments in human renal tubulointerstitial fibrosis: significance for the concept of epithelial-myofibroblast transformation. J. Submicrosc. Cytol. Pathol. 2003, 35, 221–233.
73. Leroy, P.; Mostov, K.E. Slug is required for cell survival during partial epithelial-mesenchymal transition of hgf-induced tubulogenesis. Mol. Biol. Cell 2007, 18, 1943–1952.
74. Grgic, I.; Duffield, J.S.; Humphreys, B.D. The origin of interstitial myofibroblasts in chronic kidney disease. Pediat. Nephrol. 2012, 27, 183–193.
75. Falke, L.L.; Gholizadeh, S.; Goldschmeding, R.; Kok, R.J.; Nguyen, T.Q. Diverse origins of the myofibroblast-implications for kidney fibrosis. Nat. Rev. Nephrol. 2015, 11, 233–244.
76. Inoue, T.; Umezawa, A.; Takenaka, T.; Suzuki, H.; Okada, H. The contribution of epithelialmesenchymal transition to renal fibrosis differs among kidney disease models. Kidney Int. 2015, 87, 233–238.
77. Quaggin, S.E.; Kapus, A. Scar wars: Mapping the fate of epithelial-mesenchymal-myofibroblast transition. Kidney Int.2011, 80, 41–50.
78. Takiyama, Y.; Harumi, T.; Watanabe, J.; Fujita, Y.; Honjo, J.; Shimizu, N.; Makino, Y.; Haneda, M. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: A possible role of hif-1alpha expression and oxygen metabolism. Diabetes 2011, 60, 981–992.